<DOC>
	<DOCNO>NCT01859988</DOCNO>
	<brief_summary>To assess efficacy multiple dupilumab ( REGN668/SAR231893 ) dose-regimens , compare placebo , adult patient moderate-to-severe atopic dermatitis ( AD ) .</brief_summary>
	<brief_title>Study Dupilumab ( REGN668/SAR231893 ) Administered Adult Patients With Moderate-to-Severe Atopic Dermatitis</brief_title>
	<detailed_description />
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<criteria>The inclusion criterion include , limited , follow : 1 . Chronic Atopic Dermatitis present least 3 year 2 . History inadequate response outpatient treatment topical medication , topical treatment otherwise inadvisable ( eg , important side effect safety risk ) 3 . Willing able comply clinic visit studyrelated procedure The exclusion criterion include , limited , follow : 1 . Prior treatment dupilumab ( REGN668/ SAR231893 ) 2 . Presence certain laboratory abnormality screen visit 3 . Treatment investigational drug within 8 week baseline visit 4 . Treatment live ( attenuate ) vaccine within 12 week baseline visit 5 . Certain treatment medical procedure undertake within particular timeframe prior baseline visit 6 . Known history human immunodeficiency virus ( HIV ) infection 7 . History malignancy within 5 year baseline visit ( certain exception ) 8 . Planned surgical procedure length study 9 . High risk parasite infection 10 . Any medical psychological condition , opinion investigator sponsor 's medical monitor , would place patient risk , interfere participation study interfere interpretation study result . 11 . Pregnant breastfeeding woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Eczema</keyword>
</DOC>